Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Pegylated Recombinant Human Interleukin-10 AM0010

Known as: AM0010, PEG-rHuIL-10 AM0010 
A covalent conjugate of recombinant human interleukin-10 (IL-10) and polyethylene glycol (PEG), with potential anti-fibrotic, anti-inflammatory… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
4509Background: Pegilodecakin (PEGylated hIL-10, AM0010) alone produced 25% partial responses (PR) in heavily pre-treated (median… Expand
2018
2018
374Background: The therapeutic options for 2nd line therapy PDAC remain unsatisfying with 5-FU/LV plus oxaliplatin or nal… Expand
2017
2017
399Background: The benefit of adding nal-irinotecan or oxaliplatin to 5-FU in second-line therapy for PDAC is relatively small… Expand
2017
2017
3084Background: Melanoma has a high response rate to anti-PD-1 alone. More than 50% of melanoma on anti-PD-1 progress within one… Expand
Highly Cited
2016
Highly Cited
2016
Purpose Interleukin-10 (IL-10) stimulates the expansion and cytotoxicity of tumor-infiltrating CD8+ T cells and inhibits… Expand
2016
2016
In the accompanying article, Naing et al report encouraging clinical results from a phase I trial of single-agent pegylated… Expand
  • figure 1
2016
2016
3018Background: IL-10 has anti-inflammatory properties but stimulates the cytotoxicity and proliferation of CD8 T cells. The… Expand
2016
2016
3082Background: IL-10 induces activation of STAT3 in CD8 T cells leads to increased survival, proliferation and cytotoxicity of… Expand
2015
2015
3017 Background: PEGylated IL-10 induces the expansion of tumor reactive CD8 T cells both in the periphery and within the tumor… Expand
2015
2015
Recent advances in immunoncology have dramatically changed the treatment options available to cancer patients. However, the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4